GlassScriptPhysician profile
Renjitha T Ignatius
NPI 1417163999
$20,916.24
in general payments reported to CMS, 2019-2025
88 companies · $6,253 in 2025
The $6,253 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $1,700 · 2021: $1,198 · 2022: $2,209 · 2023: $3,177 · 2024: $4,128 · 2025: $6,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,310.31 |
| Education | $247.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,339.97 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $1,328.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,186.08 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,053.92 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals LP | $964.08 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $891.60 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $804.58 | 2019-2025 | Rybrevant, Tecvayli, Erleada |
| Lilly USA, LLC | $744.40 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $702.51 | 2019-2025 | Padcev, Vyloy, Xospata |
| Celgene Corporation | $700.77 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genzyme Corporation | $567.87 | 2019-2025 | |
| Gilead Sciences, INC. | $565.89 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $525.92 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $512.76 | 2019-2025 | |
| Amgen INC. | $507.71 | 2019-2023 | Lumakras |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $501.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $462.88 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $392.59 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $379.35 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Glaxosmithkline, LLC. | $373.05 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $327.41 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Abbvie INC. | $300.03 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $286.14 | 2019-2025 | Ultomiris |
| Beigene USA, INC. | $279.96 | 2021-2025 | Brukinsa |
| Exelixis INC. | $263.06 | 2019-2025 | Cabometyx |
| Sobi, INC | $257.27 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $235.26 | 2020-2025 | |
| Stemline Therapeutics INC. | $198.13 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $197.80 | 2019-2025 | Zoladex |
| Taiho Oncology, INC. | $194.16 | 2019-2025 | |
| Array Biopharma INC | $190.03 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Beone Medicines USA, INC. | $173.52 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $173.16 | 2019-2025 | |
| Kite Pharma, INC. | $151.59 | 2020-2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $147.74 | 2024-2025 | Monoferric, Cosela |
| Emd Serono, INC. | $133.99 | 2019-2025 | Bavencio |
| Dendreon Pharmaceuticals LLC | $121.19 | 2020-2025 | Provenge |
| Foundation Medicine, INC. | $120.66 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.24 | 2019-2024 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $116.79 | 2020-2023 | Rezlidhia, Tavalisse |
| Kyowa Kirin, INC. | $114.39 | 2021-2025 | Poteligeo |
| Blueprint Medicines Corporation | $108.54 | 2023-2025 | Ayvakit |
| Genmab U.S., INC. | $108.43 | 2023-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $107.72 | 2020-2024 | Xpovio |
| Agios Pharmaceuticals, INC. | $104.42 | 2019-2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $103.77 | 2021-2025 | |
| Sirtex Medical INC | $101.29 | 2019-2020 | |
| Geron Corporation | $99.95 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $98.01 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $97.31 | 2019-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $92.16 | 2024-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $71.64 | 2022-2025 | Fotivda |
| Sumitomo Pharma America, INC. | $70.62 | 2023-2025 | Orgovyx |
| Legend Biotech USA INC. | $68.59 | 2024-2025 | Carvykti |
| Acrotech Biopharma INC. | $65.46 | 2022-2024 | Ryzneuta, Beleodaq |
| Dova Pharmaceuticals | $61.29 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $58.82 | 2022-2025 | Givlaari |
| Recordati_rare_diseases_inc. | $54.19 | 2021-2025 | Enjaymo, Sylvant |
| Deciphera Pharmaceuticals INC. | $54.07 | 2022-2025 | Qinlock, Romvimza |
| Iovance Biotherapeutics, INC. | $47.30 | 2025 | Amtagvi |
| Mirati Therapeutics, INC. | $46.27 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $43.17 | 2025 | Onivyde |
| Janssen Pharmaceuticals, INC | $39.87 | 2019 | |
| Apellis Pharmaceuticals, INC. | $38.51 | 2023-2025 | Empaveli |
| G1 Therapeutics, INC. | $34.38 | 2022-2023 | Cosela |
| Cti Biopharma Corp. | $33.08 | 2022-2023 | Vonjo |
| Novocure INC. | $30.17 | 2025 | Optune Lua (Novottf-200t) |
| Myovant Sciences INC. | $29.32 | 2021-2022 | |
| Immunogen, INC. | $29.25 | 2023 | Elahere |
| Emmaus Medical, INC. | $27.61 | 2024 | Endari |
| Amag Pharmaceuticals, INC. | $27.19 | 2019-2020 | |
| Secura Bio, INC. | $26.88 | 2022-2023 | Copiktra |
| Eusa Pharma (US) LLC | $24.84 | 2022 | |
| Immunocore Limited | $24.66 | 2025 | Kimmtrak |
| Morphosys, US INC. | $24.41 | 2023 | Monjuvi |
| Exact Sciences Corporation | $24.20 | 2025 | Cologuard Collection Kit |
| Springworks Therapeutics, INC. | $23.67 | 2024 | Ogsiveo |
| Shire North American Group INC | $23.61 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $23.52 | 2022 | |
| Boston Scientific Corporation | $23.34 | 2024 | Wavewriter Alpha Prime 16 |
| Accord Healthcare, INC. | $23.02 | 2023 | |
| Tolmar, INC. | $21.14 | 2023 | |
| Partner Therapeutics, INC. | $19.35 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.32 | 2024 | Sancuso |
| Pbg Puerto Rico LLC | $16.13 | 2020 | |
| Adc Therapeutics America, INC. | $14.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.42 | 2021 |
Drugs and devices associated with these payments
Keytruda $622Padcev $508Enhertu $493Opdivo $421Reblozyl $406Brukinsa $383Tukysa $343Jakafi $339Libtayo $334Kisqali $293Trodelvy $292Verzenio $278Ibrance $271Nubeqa $249Jaypirca $248Monjuvi $247Pluvicto $235Imfinzi $227Vyloy $226Adcetris $226Epkinly $226Elrexfio $222Ultomiris $218Ojjaara $218Lynparza $213Rybrevant $212Lenvima $202Orserdu $198Imbruvica $194Opdualag $194Xospata $184Braftovi $172Calquence $168Cabometyx $163Ninlaro $162Fruzaqla $162Lonsurf $157Inqovi $157Xofigo $157Stivarga $145Vitrakvi $145Inlyta $143Bosulif $143Doptelet $135Zoladex $133Enjaymo $132Mektovi $127Venclexta $122Tecvayli $118Zynyz $114Monoferric $110Ayvakit $109Vonjo $108Tecentriq $107Welireg $103Alunbrig $102Sarclisa $101Scemblix $101Poteligeo $101Piqray $101Orgovyx $100Rytelo $99.95Paxlovid $99.40Fabhalta $98.22Odomzo $98.01Besremi $92.16Lorbrena $91.57Polivy $91.03Xtandi $90.49Tibsovo $89.27Zepzelca $86.33Cablivi $79.04Lutathera $78.51Comirnaty $76.56Erleada $74.92Eliquis $70.22Ziihera $69.45Yonsa $66.30Elahere $64.33Zejula $61.05Jemperli $61.05Nerlynx $59.30Rezlidhia $56.68Tavalisse $56.68Cosela $54.74Talzenna $54.02Phesgo $53.67Carvykti $52.57Alecensa $52.33Darzalex $50.76Yescarta $50.27Tivdak $49.42Retevmo $48.48Amtagvi $47.30Krazati $46.27Xpovio $45.37Provenge $45.20Onivyde $43.17Givlaari $41.78Fotivda $39.67
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renjitha Ignatius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.